ForGrowth NAP B.V. sold $2.3M of NAMS
owner at NewAmsterdam Pharma Co N.V.. 91,068 shares at an average of $25.58, traded Dec 20, 2024, filed Dec 26, 2024.
Score components
- +12Role10% owner
- +25Trade size$2.3M at market
- 0Share of holdings soldSold 0.8% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-140408, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -44,143 | $25.53 | $1.1M | 10,807,853 | Dec 26, 2024 |
| Dec 20, 2024 | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -5,629 | $26.13 | $147k | 10,802,224 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -25,132 | $25.49 | $641k | 10,777,092 | Dec 26, 2024 |
| Dec 24, 2024 | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -16,164 | $25.66 | $415k | 10,760,928 | Dec 26, 2024 |
Related signals
Other insiders at NewAmsterdam Pharma Co N.V. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $1.3M 50,246 shares | -42% | |
| 38Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | Michael H. Davidson Chief Executive Officer | $227k 10,000 shares | +1% | |
| 26Weak | NAMSsell NewAmsterdam Pharma Co N.V. | John W Smither director | $41k 1,600 shares | -15% | |
| 15Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | James N Topper director | $16k 660 shares | +0% | |
| 45Moderate | NAMSsell NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $3.9M 150,000 shares | -91% | |
| 20Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | James N Topper director | $31k 1,260 shares | +0% | |
| 60Notable | NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $453k 18,073 shares | -55% | |
| 45Moderate | NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $206k 8,269 shares | -36% | |
| 68Notable | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $2.5M 100,000 shares | -59% | |
| 15Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | James N Topper director | $11k 471 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.